ArticleBMC anesthesiology2025
The effect of cerium oxide on liver in sevoflurane-administered rats: an experimental study.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevoflurane, a commonly used inhalational anesthetic, has been associated with hepatotoxicity, although reports are often isolated. Cerium oxide nanoparticles (CeO₂) are effective free radical scavengers with potential therapeutic applications for oxidative stress-related damage. This study aimed to evaluate the protective effects of CeO₂ on liver damage in sevoflurane-administered rats.
methodsA total of 24 male Wistar albino rats were randomized into four groups: Control (C), Sevoflurane (S), Cerium Oxide (CeO₂), and Sevoflurane + Cerium Oxide (S + CeO₂). Sevoflurane was administered at 2% concentration with 100% oxygen at 4 L/min for 2 h in Groups S and S + CeO₂. CeO₂ (0.5 mg/kg) was administered intravenously in Groups CeO₂ and S + CeO₂. Biochemical analyses of alanine transaminase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), hemoglobin (Hgb), and hematocrit (Hct) were performed, and liver tissues were examined histopathologically.
resultsHydropic degeneration and neutrophil infiltration were significantly lower in Group CeO₂ compared to Group S. Group S showed elevated AST and LDH levels compared to the control (p < 0.05). Although AST levels were lower in Groups CeO₂ and S + CeO₂ than in Group S, the difference was not statistically significant. LDH levels were significantly lower in Group S + CeO₂ compared to Group S (p = 0.045). Histopathological examination confirmed reduced liver damage in CeO₂-treated groups.
conclusionsThis study is of significance since it is the first experimental study on the effect of CeO2 on liver damage caused by sevoflurane. Cerium oxide demonstrated potential in mitigating sevoflurane-induced liver damage. Further research is warranted to explore the clinical relevance of CeO₂ in hepatic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.